早期非小细胞肺癌患者血清巨噬细胞抑制因子-1、趋化素与临床病理特征及预后的关系

目的:探讨早期非小细胞肺癌(NSCLC)患者血清巨噬细胞抑制因子-1(MIC-1)、趋化素(chemerin)水平与临床病理特征及预后的关系。方法:选择72例NSCLC患者(NSCLC组)、53例肺良性疾病患者(良性组)、50例体检健康人群(对照组),分别检测血清MIC-1、chemerin水平,分析血清MIC-1、chemerin水平与NSCLC患者临床病理参数的关系。Kaplan-Meier法分析不同血清MIC-1、chemerin水平NSCLC患者生存时间的差异,COX比例风险回归分析血清MIC-1、chemerin水平与NSCLC患者预后的关系。结果:NSCLC组患者血清MIC-1、chemerin水平高于良性组和对照组(P0.05)。血清MIC-1水平与NSCLC患者年龄、目前吸烟、肿瘤直径、TNM分期、分化程度、复发或转移、生存状态有关(P0.05),chemerin水平与NSCLC患者目前吸烟、TNM分期、复发或转移、生存状态有关(P0.05)。高MIC-1水平患者生存率低于低MIC-1水平患者(P0.05),高chemerin水平患者生存率低于低chemerin水平患者(P0.05)。COX比例风险回归分析结果显示:血清MIC-1、chemerin、TNM分期与NSCLC不良预后独立相关。结论:血清MIC-1、chemerin水平与NSCLC患者部分临床病理参数和预后相关,可作为早期NSCLC患者预后预测的潜在指标。

Relationship between Serum Macrophage Inhibitor-1, Chemokine and Clinicopathological Features and Prognosis in Patients with Early Non-small Cell Lung Cancer

ABSTRACT Objective: To investigate the relationship between serum level of macrophage inhibitory factor-1 (MIC-1) and chemerin and clinicopathological features and prognosis in patients with early non-small cell lung cancer (NSCLC). Methods: 72 patients with NSCLC (NSCLC group), 53 patients with benign pulmonary diseases (benign group) and 50 healthy people (control group) were selected. Serum MIC-1 and chemerin levels were detected respectively. The relationship between serum MIC-1 and chemerin levels and clinicopathological parameters of NSCLC patients was analyzed. The survival time of NSCLC patients with different serum levels of MIC-1 and Chemerin was analyzed by Kaplan-Meier method. The relationship between serum levels of MIC-1 and chemerin and the prognosis of NSCLC patients was analyzed by COX proportional risk regression. Results: The serum MIC-1 and chemerin levels in NSCLC group were higher than those in benign group (P<0.05). Serum MIC-1 level was correlated with age, current smoking, tumor diameter, TNM stage, differentiation degree, recurrence or metastasis, survival status of NSCLC patients (P<0.05), and chemerin level was correlated with current smoking, TNM stage, recurrence or metastasis and survival status of NSCLC patients (P<0.05). The survival rate of patients with high MIC-1 level was lower than that of patients with low MIC-1 level (P<0.05), and survival rate of patients with high chemerin level was lower than that of patients with low chemerin level (P<0.05). COX proportional risk regression analysis showed that serum MIC-1, chemerin and TNM stage levels were independently associated with poor prognosis of NSCLC. Conclusion: Serum MIC-1 and chemerin levels are correlated with some clinicopathological parameters and prognosis of NSCLC patients, and they can be used as potential prognostic indicators for early NSCLC patients.